Evidence map›Paper›PMID 34650912›Full record

ArticleFrontiers in oncology2021

Factors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy.

Alice Hours, Aullene Toussaint, Victoire De Castelbajac, Camille Sautter, Julie Borghese, Sophie Frank, Florence Coussy, Enora Laas, Beatriz Grandal, Elise Dumas and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 1 country.

Alice HoursDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Aullene ToussaintDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Victoire De CastelbajacDepartment of Medical Oncology, Institut Curie, University Paris, Paris, France.
Camille SautterDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Julie BorgheseResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Sophie FrankDepartment of Medical Oncology, Institut Curie, University Paris, Paris, France.
Florence CoussyDepartment of Medical Oncology, Institut Curie, University Paris, Paris, France.
Enora LaasDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Beatriz GrandalResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Elise DumasResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Eric DaoudResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Julien GuerinData Factory, Institut Curie, Paris, France.
Thomas BalezeauData Factory, Institut Curie, Paris, France.
Jean-Guillaume FeronDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Virginie FourchotteDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Youlia KirovaDepartment of Radiation Therapy, Institut Curie, Paris, France.
Florence LereboursResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Jean-Yves PiergaResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Eugénie GuillotDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Pietro SantulliDepartment of Obstetrics and Gynecology, Hôpital Cochin, University Paris, Paris, France.
Michael GrynbergDepartment of Reproductive Medicine and Fertility Preservation, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris Sud, Assistance Publique - Hôpitaux de Paris, Clamart, France.
Charlotte SonigoDepartment of Reproductive Medicine and Fertility Preservation, Hôpital Antoine Béclère, Hôpitaux Universitaires Paris Sud, Assistance Publique - Hôpitaux de Paris, Clamart, France.
Emmanuel ReyratDepartment of Data and Informatics, Unicancer, Paris, France.
Pauline Soibinet-OudotDepartment of Medical Oncology, Godinot Institute, Reims, France.
Fabien ReyalDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Anne-Sophie HamyDepartment of Surgery, Institut Curie, University Paris, Paris, France.
Institut Curie · FRImmunité et Cancer · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Cochin · FRHôpital Jean-Verdier · FRInstitut Jean Godinot · FRUniCancer Group · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFemale breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence of disparities in the discussion of fertility preservation for these patients. The aim of the study was to identify factors influencing the discussion of fertility preservation (FP). MATERIAL AND

methodsWe analyzed consecutive BC patients treated by chemotherapy at Institut Curie from 2011-2017 and aged 18-43 years at BC diagnosis. The discussion of FP was classified in a binary manner (discussion/no discussion), based on mentions present in the patient's electronic health record (EHR) before the initiation of chemotherapy. The associations between FP discussion and the characteristics of patients/tumors and healthcare practitioners were investigated by logistic regression analysis.

resultsThe median age of the 1357 patients included in the cohort was 38.7 years, and median tumor size was 30.3 mm. The distribution of BC subtypes was as follows: 702 luminal BCs (58%), 241 triple-negative breast cancers (TNBCs) (20%), 193 HER2

conclusionFP discussion rates are low and are influenced by patient and physician characteristics. There is therefore room for improvement in the promotion and systematization of FP discussion.

Indexed as

breast cancerchemotherapydiscussionfertility preservationoncofertility

Identifiers

PMID34650912
PMCPMC8507557
OpenAlexW3204158629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.